Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CRB Bio II and ADE Capital Sodical Commits €3M Seed Investment Round

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Raman Health Technologies develops a new non invasive diagnostic technology platform for multiple diseases based on Raman laser spectroscopy.

CRB Bio II and ADE Capital Sodical have committed a €3M seed investment round in Raman Health Technologies, a new start up company developing a new non invasive diagnostic technology platform based on Raman laser and Infrared spectroscopy. Its first indication will be for the early diagnosis of Alzheimer disease in a blood sample.

Raman Health, based at the Boecillo Technology Park, is a spin-off of the University of Valladolid Fernando Rull, Professor of Crystallography and Mineralogy of the University of Valladolid is one of the key persons in this project.

This financing round will allow the company to achieve its strategic objectives, namely the establishment of a new expanded lab facility to foster the development of the methodology for the detection of spectroscopic biomarkers and the development of a robust diagnostic platform.

Laser to detect Alzheimer
The platform being developed by Raman Health Technologies will be used for the diagnosis of different diseases in a blood sample.

In the case of Alzheimer disease, it avoids the need of invasive techniques, like the lumbar punction to obtain cerebrospinal fluid and will provide a significant improvement in costs and logistics compared to Imaging Technologies (NMR or PET).

Additionally, based on its capability to identify different biological substances, the spectroscopy of Raman Health Technologies can provide simultaneously information of several biomarkers with just one spectroscopic reading.

When compared to other diagnostic technologies, Raman-Laser based spectroscopy is faster, less invasive and cheaper. Additionally no reagents are needed. Raman Health Technologies can change the diagnosis of complex diseases like Alzheimer.

CRB Bio II third investment
This transaction is the third investment made by CRB Bio II, one of the largest specialized Life Science Funds in Spain, after those made in Oncovision and Amadix, for a total aggregated investment in excess of €3,5M.

“This last investment underscores our commitment to invest in disruptive technologies at early stage of development in life sciences. In the case of Raman Health Technologies, this is a very cost-effective technology, with a terrific potential and multiple application areas.” says Pablo Cabello, CSO of CRB Inverbío.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!